Heritability of lifetime ecstasy use.
Karin J H Verweij, Jorien L Treur, Annabel Vreeker, Tibor M Brunt, Gonneke Willemsen, Dorret I. Boomsma, Jacqueline M Vink
Drug and Alcohol Dependence September 1, 2017 DOI: 10.1016/j.drugalcdep.2017.05.007 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Twin study Peer reviewed |
|---|---|
| Sample size | 8,500 |
| Population | Twins and siblings aged 18-45 years from 5,402 families registered at the Netherlands Twin Registry |
| Topics | MDMA |
| Keywords | Genetics Heritability Substance use Twin study |
| Key points | Individual differences in liability to lifetime ecstasy use were estimated to be 74% due to genetic differences, with shared environmental factors explaining 5% and residual factors 21%. Overall, 10.4% of the sample reported lifetime ecstasy use, with a somewhat higher prevalence in males; the apparent higher heritability in females was not statistically significant. |
Abstract
Ecstasy is a widely used psychoactive drug that users often take because they experience positive effects such as increased euphoria, sociability, elevated mood, and heightened sensations. Ecstasy use is not harmless and several immediate and long term side effects have been identified. Lifetime ecstasy use is likely to be partly influenced by genetic factors, but no twin study has determined the heritability. Here, we apply a classical twin design to a large sample of twins and siblings to estimate the heritability of lifetime ecstasy use. The sample comprised 8500 twins and siblings aged between 18 and 45 years from 5402 families registered at the Netherlands Twin Registry. In 2013-2014 participants filled out a questionnaire including a question whether they had ever used ecstasy. We used the classical twin design to partition the individual differences in liability to ecstasy use into that due to genetic, shared environmental, and residual components. Overall, 10.4% of the sample had used ecstasy during their lifetime, with a somewhat higher prevalence in males than females. Twin modelling indicated that individual differences in liability to lifetime ecstasy use are for 74% due to genetic differences between individuals, whereas shared environmental and residual factors explain a small proportion of its liability (5% and 21%, respectively). Although heritability estimates appeared to be higher for females than males, this difference was not significant. Lifetime ecstasy use is a highly heritable trait, which indicates that some people are genetically more vulnerable to start using ecstasy than others.
Citations in the library
Cites 7
- A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers Journal of Psychopharmacology March 1, 2006
- The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. Journal of Psychopharmacology September 1, 2006
- 3,4-methylenedioxymethamphetamine (MDMA): current perspectives Substance Abuse and Rehabilitation November 1, 2013
- Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence September 3, 2015
- MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. Drug and Alcohol Dependence February 1, 2012
and 2 more in the library